breaking

Trump Administration Fast-Tracks Psychedelic Therapy Research for PTSD, Depression

President Donald Trump signed an executive order in April aimed at accelerating research into psychedelic treatments for mental health conditions including post-traumatic stress disorder and depression. The administration granted priority review vouchers to three companies developing psychedelic and MDMA-based therapies: Compass Pathways, Usona Institute and Transcend Therapeutics. The vouchers are designed to expedite FDA review processes for these treatments. The policy marks a significant departure from Trump's first administration, which pursued stricter enforcement against controlled substances. Clinical trials are already underway, with veterans and other patients participating in psychedelic-assisted therapy programs. While advocates view the initiative as progress, questions remain about safety as research continues. The move creates both opportunities for patients seeking alternative mental health treatments and expansion prospects for developing companies, though safety and effectiveness require continued scrutiny.